Introduction
============

Microorganisms produce a highly diverse array of compounds that can be harnessed as anti-bacterial agents.[@cit1] Bacteriocins are ribosomally synthesized and post-translationally modified peptides (RiPPs) secreted by bacteria as a primary defence mechanism against competing bacteria.[@cit2] Bacteriocins from lactic acid bacteria have received considerable attention due to a desirable safety profile, stability across wide pH and temperature ranges, antimicrobial activity against various pathogens, and no cross-resistance with antibiotics.[@cit3]--[@cit5] These features have prompted interest in bacteriocins as novel antimicrobial agents, probiotics and natural preservatives.[@cit4]

Glycocin F (GccF, **1**) is a potent bacteriocin originally isolated from liquid culture of *Lactobacillus plantarum* KW30.[@cit6] GccF is a 43-residue helical peptide that contains two interlocked disulfide bonds (^5^Cys--^28^Cys and ^12^Cys--^21^Cys) and two β-linked *N*-acetyl-[d]{.smallcaps}-glucosamine (GlcNAc) moieties, connected to the side chain of ^18^Ser *via* the oxygen atom and ^43^Cys *via* the sulfur atom.[@cit7] The glycosylated cysteine, in particular, is an extremely rare post-translational modification in bacteria and has only been found in two other glycopeptides to date (sublancin and thurandacin).[@cit8]--[@cit10] GccF exhibits bacteriostatic activity against a relatively wide range of Gram positive bacteria, with *L. plantarum* strains suspected to be its natural target.[@cit6],[@cit7] Notably, ASM1, a close homologue of GccF, and enterocin 96 are the only glycosylated bacteriocins which have been shown to be "glycoactive",[@cit11]--[@cit13] that is, the saccharide moieties are essential for biological activity. In a previous study, removal of the GlcNAc attached to ^18^Ser completely abolished the activity, while removal of the *C*-terminal fragment ^42^His--^43^Cys(β-GlcNAc) reduced the activity 44-fold.[@cit7] The *C*-terminal *S*-glycosidic linkage is of particular interest, as the natural functions of such bonds remain unclear. Further, the improved biochemical stability of *S*-glycoside linkages[@cit14] compared to their *O*-linked congeners provides considerable scope for the development of *S*-glycosylated bacteriocins as both preservatives and therapeutics.

Since the discovery of GccF (**1**), attempts to dissect its molecular mechanism and cellular targets have been hampered by the inefficiency of its isolation from cultures of *L. plantarum*. Chemical synthesis of complex bacteriocin glycopeptides is an attractive alternative to direct isolation or recombinant production as it offers atomic-level control over peptide sequence and modifications. However, few total syntheses of glycosylated bacteriocins have been reported to date. An example is the synthesis of 37-residue sublancin 168 by Payne *et al.*[@cit9]*via* solid-phase peptide synthesis coupled with a convergent ligation methodology. Two other glycosylated bacteriocins thurandacin and enterocin 96 have been prepared using chemoenzymatic methods.[@cit8],[@cit13]

We have previously reported[@cit11] the first synthesis of a biologically active form of GccF, identical in structure to the natural product except for *C*-terminal amidation. The synthetic *C*-terminal amide analogue of GccF exhibited a reduced bacteriostatic activity compared to the natural peptide derived from *L. plantarum* culture.[@cit11] We therefore sought to obtain the native GccF that contains the *C*-terminal acid to determine the role of the *C*-terminal carboxylate. We then sought to extend this further by chemically synthesizing 'glyco-mutants' of GccF to examine the chemical linkage between the peptide backbone and the GlcNAc. Our hypothesis is that replacing *O*-linked sugars with *S*-linked sugars would not greatly perturb the structural requirements of GccF, thereby preserving the bioactivity but may also result in enhanced enzymatic stability.[@cit14]

Herein, the native form of glycocin F (**1**) was prepared and improvements on its chemical synthesis are reported. Notably, the synthetic GccF is equipotent to the isolated material in a liquid culture assay. Furthermore, several 'glyco-mutants' of GccF were generated, in which both of the two native glycosylation sites (^18^Ser and ^43^Cys) were substituted with *S*-linked β-GlcNAc (Cys(β-GlcNAc)) or *O*-linked β-GlcNAc (Ser(β-GlcNAc)) residues. These analogues have enabled us to better understand the contributions of each sugar linkage to the bacteriostatic activity of glycocin F and reveal the considerable potential of *S*-linked glycoconjugates as antimicrobial agents.

Results and discussion
======================

Synthesis of glycocin F (**1**)
-------------------------------

The synthetic strategy to prepare native glycocin F (**1**) was analogous to that described for the previous synthesis of *C*-terminally amidated glycocin F.[@cit11] In that report, we adopted a three fragment native chemical ligation (NCL) strategy as depicted in [Scheme 1](#sch1){ref-type="fig"}. In the present work we employed the 2-chlorotrityl linker for the preparation of the racemisation-prone *C*-terminal acid fragment **2**, bearing a *C*-terminal cysteine (ESI Fig. 14 and Scheme 5[†](#fn1){ref-type="fn"}). The use of benzyl alcohol-based linkers was avoided as the esterification conditions for loading a cysteine residue to such linkers can lead to Cα racemisation and/or dehydroalanine by-product formation.[@cit15] 2-Chlorotrityl based resins does not involve carboxylate activation and thus does not result in racemisation. In our previous synthesis of glycocin F-amide, the 4-(4-hydroxymethyl-3-methoxyphenoxy)-butyric acid (HMPB) linker was used to prepare fragment **3**, causing substantial racemisation at ^27^His; pleasingly changing the linker to 2-chlorotrityl linker reduced this to *ca.* 20%.

![Synthesis of GccF (**1**) and \[^27^[d]{.smallcaps}-His\]-GccF, with the problematic His highlighted in red. Reagents and conditions: (i) 6 M Gn·HCl, 0.2 M Na~2~HPO~4~, 100 mM MPAA, 20 mM TCEP, pH 6.8, r.t, 2 h; (ii) 6 M Gn·HCl, 0.2 M Na~2~HPO~4~, methoxylamine·HCl, pH 4, r.t, 16 h; (iii) 6 M Gn·HCl, 0.2 M Na~2~HPO~4~, 100 mM MPAA, 20 mM TCEP, pH 6.8, r.t, 4 h; (iv) 6 M Gn·HCl, 1 M HEPES, hydrazine, 2-mercaptoethanol, 0 °C, 30 min; (v) 1.5 M Gn·HCl, 50 mM Na~2~HPO~4~, 2 mM cysteine, 0.25 mM cystine, 0.025 mM EDTA, 0.25 mM peptide, pH 8.2, 4 °C, 16 h.](c7sc04383j-s1){#sch1}

The necessary *O*-glycosylated amino acid Fmoc-Ser(β-GlcNAc(OAc)~3~)-OH (Fmoc = 9-fluorenylmethoxycarbonyl) and *S*-glycosylated amino acid Fmoc-Cys(β-GlcNAc(OAc)~3~)-OH building blocks were prepared as previously described (ESI Scheme 1[†](#fn1){ref-type="fn"}). Native chemical ligation was undertaken as before and the fully assembled linear peptide was folded without incident (ESI Fig. 23 and 24[†](#fn1){ref-type="fn"}). Purification by HPLC yielded epimeric glycocin F (**1a**) and glycocin F (**1b**) in 29% and 32% yield, respectively.

The presence of the two disulfide bonds in **1b** was confirmed by HRESI-MS analysis (HR-ESIMS, *m*/*z* \[M + 4H\]^4+^; calculated for C~226~H~311~N~57~O~72~S~7~: 1041.4634, observed: 1040.8167) (ESI Fig. 26[†](#fn1){ref-type="fn"}). Glycocin F glycopeptides **1a** and **1b**, epimeric at ^27^His, were then compared with an authentic sample of glycocin F isolated from *L. plantarum* (ESI Fig. 25[†](#fn1){ref-type="fn"}) and assignment of the natural product was achieved by direct comparison of the HPLC retention time. Epimer **1b** eluted at an identical retention time to the isolated material and therefore was assigned the [l]{.smallcaps}-configuration at ^27^His. In contrast, epimer **1a** eluted earlier and was therefore assigned the [d]{.smallcaps}-configuration.

The secondary structure of synthetic folded GccF was determined by circular dichroism (CD) spectroscopy. Similar to the isolated GccF, the synthetic derivative **1b** and epimeric analogue **1a** exhibit the features expected for α-helical proteins, namely standard double negative ellipticity maxima at 210 and 221 nm, and a positive maximum near 194 nm (ESI Fig. 43[†](#fn1){ref-type="fn"}).

Second-generation synthetic strategy provides expedient access to 'glyco-mutants' of glycocin F
-----------------------------------------------------------------------------------------------

### A.. Development of a two-fragment, single ligation strategy

In order to systematically examine structure--activity relationships of complex glycopeptides such as GccF (**1**), a large number of mutations must be made to enable dissection of each residue\'s contribution to activity. We therefore sought to develop a more efficient synthesis of GccF and analogues that would enable rapid production of a library of such mutants, at a scale sufficient for biochemical characterisation. The above-described strategy to prepare GccF involved synthesis of three polypeptide fragments that underwent two consecutive NCL reactions to produce full-length GccF. An alternative strategy was devised ([Scheme 2](#sch2){ref-type="fig"}) using only two fragments, consisting of a 32-amino acid digylcosylated fragment **5**, \[^12^Cys--^18^Ser(β-GlcNAc(OAc)~3~)--^43^Cys(β-GlcNAc(OAc)~3~)\] and the *N*-terminal fragment **6**, \[^1^Lys--^11^Met-COSCH~2~CH~2~--(Lys)~5~\]. While the previous synthesis of fragment **5** had required the ligation of the two short peptides **2** and **3** followed by ^12^Thz deprotection, we anticipated that **5** could be accessed through direct Fmoc-SPPS with higher yield. Following this approach, the native residue ^12^Cys could be used as the ligation site between **5** and **6**, thereby avoiding introduction of a non-native thiazolidine that would require further chemical manipulation after the ligation step. Critically, a single-ligation strategy would by-pass the problematic thioesterification step at ^27^His, avoiding racemisation at this residue.

![Optimised synthesis of GccF fragment **9**, which was then employed for the synthesis of glycol-mutants **10** and **11**. Reagents and conditions: (i) Fmoc-[l]{.smallcaps}-Cys(β-GlcNAc(OAc)~3~)-OH for **9** and **13** or Fmoc-[l]{.smallcaps}-Ser(β-GlcNAc(OAc)~3~)-OH for **12**, *i*Pr~2~EtN, CH~2~Cl~2~, r.t, 1 h; (ii) Fmoc-SPPS (Fmoc deprotection: 20% piperidine in DMF (v/v)), r.t, (2 × 5 min); coupling: Fmoc-amino acid, HATU, *i*Pr~2~EtN, DMF, r.t, 40 min except Fmoc-^18^Ser(β-GlcNAc(OAc)~3~)-OH, HATU, HOAt, TMP, DMF, r.t, overnight and Fmoc-^21^Cys(Trt)-OH, HATU, HOAt, TMP, CH~2~Cl~2~: DMF (1 : 1, v/v), r.t, 2 × 1 h; (iii) 94% TFA, 2.5% EDT, 2.5% H~2~O, 1% *i*Pr~3~SiH (v/v/v/v), r.t, 2 h; (iv)--(vi) for **14** and **15**, (iv) 6 M Gn·HCl, 0.2 M Na~2~HPO~4~, 100 mM MPAA, 20 mM TCEP, pH 6.8, r.t, 4 h; (v) 6 M Gn·HCl, 1 M HEPES, hydrazine, 2-mercaptoethanol, 0 °C, 30 min; (vi) 1.5 M Gn·HCl, 50 mM Na~2~HPO~4~, 2 mM cysteine, 0.25 mM cystine, 0.025 mM EDTA, 0.25 mM peptide, pH 8.2, 4 °C, 16 h.](c7sc04383j-s2){#sch2}

Direct synthesis of fragment **5** was initiated on 2-ClTrtCl-polystyrene resin ([Scheme 2](#sch2){ref-type="fig"}), and subsequent peptide elongation was performed *via* Fmoc-SPPS using HATU/*i*Pr~2~EtN as the coupling reagent and 20% piperidine/DMF (v/v) as the Fmoc deblocking reagent. As peptide aggregation and thus reduced coupling yields had hindered previous efforts to synthesise this long fragment, three pseudoproline dipeptides[@cit16],[@cit17] were incorporated within the peptide chain, namely ^19^Gly--^20^Thr, ^25^Tyr--^26^Ser, and ^35^Ser--^36^Ser. Previous analysis of a truncated fragment ^16^Gly--^27^His, built on 2-ClTrtCl-based resin, revealed the presence of a significant, contaminating by-product (25% relative to expected peptide) with the same mass, which was attributed to ^21^Cys racemisation (ESI Fig. 27[†](#fn1){ref-type="fn"}). In order to prevent this, the coupling of ^21^Cys was achieved using HATU and 2,4,6-trimethylpyridine (TMP) in the presence of 1-hydroxy-7-azabenzotriazole (HOAt) in CH~2~Cl~2~/DMF (v/v; 1 : 1), conditions known to suppress racemisation.[@cit18],[@cit19] Following Fmoc-SPPS, the fully assembled peptide **9** was recovered from the resin with simultaneous removal of side chain protecting groups using the cleavage mixture TFA/EDT/H~2~O/*i*Pr~3~SiH (v/v/v/v; 94 : 2.5 : 2.5 : 1). Under the above conditions, the desired glycopeptide **5** was successfully obtained in 30% crude yield and \>73% purity, with successful inhibition of ^21^Cys racemisation and avoiding ^27^His racemisation (ESI Fig. 28[†](#fn1){ref-type="fn"}).

### B.. Generation of 'glyco-mutants' of glycocin F

As glycocin F (**1**) was already synthesised, its preparation from glycopeptide **5** using the optimised synthetic strategy was not undertaken. Instead, we employed the improved methodology for the synthesis of 'glyco-mutant' analogues of glycocin F. Thus, two analogues of glycocin F (peptides **10** and **11**) were prepared, each bearing a single modification at one of the glycoside positions. Thus, analogue **10** was designed to contain *O*-linked GlcNAc moieties at amino acid positions 18 and 43. To prepare this analogue, the *C*-terminal ^43^Cys(β-GlcNAc) was replaced with a Ser(β-GlcNAc). Analogue **11** was designed to have *S*-linked GlcNAc moieties at positions 18 and 43. To achieve this, the internal ^18^Ser(β-GlcNAc) was replaced with a Cys(β-GlcNAc). Both analogues were designed to elucidate the biological rationale for incorporation of an *S*-glycosidic linkage in native glycocin F. The requisite resin-bound fragments **12** and **13** containing the desired glycosides, were synthesised in an analogous fashion to that described above for peptide **9** ([Scheme 2](#sch2){ref-type="fig"} and ESI Fig. 29 and 30[†](#fn1){ref-type="fn"}). Polypeptides **14** and **15** were then individually ligated with the N-terminal fragment, peptide thioester ^1^Lys--^11^Met-COSCH~2~CH~2~--(Lys)~5~**6**. NCL reactions were performed as described previously (6 M Gn·HCl, 0.2 M Na~2~HPO~4~, 20 mM TCEP, and 100 mM MPAA, pH 6.8) at a final peptide concentration of 1 mM, and provided the ligation products in good yields (40% from **12**, and 44% from **13**) (ESI Schemes 31 and 33[†](#fn1){ref-type="fn"}). The ligation products were subjected to simultaneous formyl and acetyl deprotection, purified by RP-HPLC and subjected to oxidative folding, following the procedures developed above for the preparation of GccF **1**. Each 'glyco-mutant' of GccF folded successfully to afford a single folded species, as determined by HPLC, within 16 h (ESI Fig. 39 and 41[†](#fn1){ref-type="fn"}). The presence of two disulfide bonds in each analogue was confirmed by high resolution mass spectrometry (HRMS) with an observed mass for glyco-mutants **10** and **11**, of 1037.6213 (\[M + 5H\]^5+^) and 1044.0121 (\[M + 5H\]^5+^) Da, respectively, consistent with the calculated masses of the desired products (ESI Fig. 40 and 42[†](#fn1){ref-type="fn"}).

The secondary structure of glyco-mutants **10** and **11** was determined by circular dichroism (CD) spectroscopy, which confirmed a similar α-helical structure to the native glycosin F bacteriocin (ESI Fig. 43[†](#fn1){ref-type="fn"}).

Biological evaluation of synthetic GccF (**1b**) and \[^27^[d]{.smallcaps}-His\]-GccF and "glyco-mutants"
---------------------------------------------------------------------------------------------------------

Recent research from one of our laboratories (Norris) implicates a GlcNAc-specific phosphotransferase system (PTS) transporter in the cell membranes of susceptible Gram-positive bacteria as the likely target of glycocin F. It is hypothesised that glycocin F binds to the transmembrane domain of its receptor through the tethered GlcNAc residues and disrupts sugar-processing and regulatory activities essential for bacterial growth. Although the exact details remain unknown, a full understanding of the mechanism of action of glycocin F will afford a unique opportunity to develop an entirely new suite of PTS-targeted glycoconjugate antimicrobials for therapeutic and industrial application.

To evaluate the antibacterial activity of synthetic glycocin F (**1b**), \[^27^[d]{.smallcaps}-His\]-GccF (**1a**) and glyco-mutants **10** and **11**, the IC~50~ values against *Lactobacillus plantarum* ATCC 8014 were measured using a liquid culture assay. Synthetic GccF (**1b**) was used as the positive control ([Table 1](#tab1){ref-type="table"}).

###### Activity of bacterially isolated GccF, the synthesised GccF peptides and GccF glyco-mutants

  Compound \#   Modification                       IC~50~
  ------------- ---------------------------------- ----------------
  **Native**    Isolated GccF                      2.0 ± 0.20 nM
  **1b**        Synthetic GccF                     1.13 ± 0.20 nM
  **1a**        \[^27^[d]{.smallcaps}-His\]-GccF   0.98 ± 0.17 nM
  **10**        ^43^Cys(GlcNAc) to Ser(GlcNAc)     12.1 ± 0.20 nM
  **11**        ^18^Ser(GlcNAc) to Cys(GlcNAc)     0.60 ± 0.10 nM

The IC~50~ of the bacterially produced glycocin F was found to be 2.0 ± 0.20 nM. The synthetic glycocin F (**1b**) exhibited an enhanced antibacterial activity relative to this batch of isolated material (IC~50~ = 1.13 ± 0.20 nM). Considering that the previously reported GccF-NH~2~ exhibited reduced bacteriostatic activity (IC~50~ = 1.6 nM),[@cit11] this current result provides insight into the relationship of the target glycopeptide with its target receptor: amidation of the *C*-terminus was in fact responsible for the reduced effect, implying that a positively charged residue within the receptor may be interacting with the negatively charged carboxylate *C*-terminus.

The importance of the *C*-terminal carboxylate for bioactivity was also verified from the IC~50~ value of \[^27^[d]{.smallcaps}-His\]-GccF (**1a**) (0.98 ± 0.17 nM). Interestingly, the previously reported \[^27^[d]{.smallcaps}-His\]-GccF-NH~2~ showed a significant reduction in activity (IC~50~ = 4.8 nM) compared to both isolated GccF and GccF-NH~2~, suggesting that incorporation of [d]{.smallcaps}-His negatively influences bioactivity. However, we herein show that the previously reported reduction in bioactivity of the \[^27^[d]{.smallcaps}-His\]-GccF-NH~2~ was in fact a consequence of the *C*-terminal amidation.

The antibacterial activity of the two glyco-mutants, **10** and **11** revealed an intriguing trend. The activity of glycocin F analogue **10**, which contains two *O*-linked GlcNAc moieties, exhibited decreased activity (approximately 10-fold, IC~50~ = 12.1 ± 0.20 nM) compared to the native glycocin F (IC~50~ = 1.13 ± 0.20 nM). Notably, the activity of analogue **11**, which contains two *S*-linked GlcNAc moieties, was increased by approximately 2-fold (IC~50~ = 0.60 ± 0.10 nM) relative to the native glycopeptide. Thus, in this series, the bacteriostatic activity is enhanced by replacing the *O*-glycoside with an *S*-glycoside, with the maximum activity obtained by glycopeptide **11** bearing *S*-linked GlcNAc at both residues 18 and 43.

This striking result is predicted to be due to the enhanced resistance of the stable *S*-glycosidic linkages to hydrolytic cleavage compared to *O*-glycosidic linkages, when exposed to the cell envelope and/or secreted glycosidases of target bacteria. Indeed, the Pratt group has recently demonstrated the resistance of *S*-linked GlcNAc to cleavage by human *O*-GlcNAcase (OGA).[@cit14] By avoiding enzymatic cleavage, the *S*-linked GlcNAc moieties could remain available for binding at the GccF target receptor, leading to enhanced potency and prolonged bacteriostasis.

Conclusions
===========

The first total synthesis of native glycocin F **1**, containing both *S*- and *O*-linked β-GlcNAc moieties, was accomplished using a three-fragment NCL strategy followed by oxidative folding. Structural identity to the naturally isolated glycocin F was confirmed by analytical RP-HPLC and CD spectroscopy. To avoid troublesome racemisation at ^27^His and to increase the overall efficiency of glycocin F synthesis, an alternative synthetic strategy was successfully developed using a two-fragment NCL strategy. This strategy was then employed for the synthesis of two 'glyco-mutant' analogues of glycocin F (**10** and **11**), each bearing a single modification at one of the residues bearing a sugar moiety. Strikingly, the bioactivity increased significantly when the sequence incorporated two *S*-GlcNAc moieties at positions 18 and 43 (in peptide **11**).

The results reported herein highlight the potential of glycocin F analogue **11** and related *S*-linked glycoconjugates as leads for the development of new anti-bacterial agents. Our preparation of glycocin F and analogues aims to provide fundamental insights into a novel antimicrobial mechanism of action, knowledge that is vital for the successful conversion of natural products into the 'smart antibiotics' needed for future therapies and industrial applications.
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